Ironwood Pharmaceuticals | IRWD - Ebitda


Ironwood Pharmaceuticals reported $81.81M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Almirall EUR 80.45M 33.61M Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amarin USD 12.54M 28.57M Jun/2025
Ardelyx USD -9.78M 19.98M Jun/2026
Astellas Pharma JPY 182.02B 53.22B Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Charles River Laboratories USD 298.04M 25.1M Sep/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Halozyme Therapeutics USD 336.16M 7.34M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
MacroGenics USD -64.54M 34.34M Jun/2026
Moderna USD -687M 571M Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Pacira USD 50.45M 1.78M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Takeda JPY 369.75B 5.29B Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024